DUBLIN, Dec 7, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19" report to their offering.
Global Revenues for the Cancer Vaccines Market are Forecast to grow at a CAGR of 16.93%, from $2.5 Billion in 2015 to $7.5 Billion in 2022
Cancer vaccines are being developed as a method of preventing certain types of cancer, and as therapeutic treatments to treat existing cancers across a range of indications in oncology, either as stand-alone therapies or in combination with traditional cancer therapeutics such as chemotherapy and surgery. The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies, which have a lower toxicity associated with their use than traditional chemotherapies.
Therapeutic vaccine administration will increase the overall survival of poor-performance-status patients, and enable more rounds of treatment to be given - factors that will contribute to growing global revenues for this class of therapy. However, cancer vaccines are not perceived as having strong commercial potential, as immune checkpoint inhibitors are expected to dominate the treatment landscape for leukemia and lymphoma during the forecast period.
A number of common etiologic factors have been strongly characterized as raising the risk of developing cancer, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive cancer prevalence and revenue growth for its treatments.
Prophylactic vaccines are currently used to immunize against viruses, which have been shown to increase the risk of cancer, with viral factors being the underlying cause of approximately 15% of cancers worldwide. Prophylactic vaccines such as Gardasil are currently the most commercially successful and well-established class of cancer vaccines.
However, there has been a shift towards the clinical testing of therapeutic vaccines - which constitute the majority of the pipeline - such as Imlygic, which was recently approved for melanoma.
Key Topics Covered:
1 Tables & Figures
3 Key Marketed Products
4 Pipeline Landscape Assessment
5 Multi-scenario Market Forecast to 2022
6 Company Analysis and Positioning
7 Strategic Consolidations
For more information about this report visit http://www.researchandmarkets.com/research/4fd77q/global_cancer
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cancer-vaccines-market-2015-2022---how-will-the-market-shares-and-cagrs-of-the-top-20-pharma-companies-compare-within-cancer-vaccines---research-and-markets-300374607.html
SOURCE Research and Markets